Scott Ullem Sells 7,700 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) CFO Scott Ullem sold 7,700 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $1.14 during midday trading on Tuesday, reaching $83.18. 2,412,453 shares of the company traded hands, compared to its average volume of 4,464,232. The firm has a market cap of $48.27 billion, a PE ratio of 35.86, a price-to-earnings-growth ratio of 3.82 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm’s 50 day simple moving average is $81.09 and its two-hundred day simple moving average is $78.83. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. The company’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Sanford C. Bernstein reiterated a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 29th. Piper Sandler reissued an “overweight” rating and set a $95.00 target price (up from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. UBS Group set a $92.00 target price on Edwards Lifesciences in a research report on Friday. Finally, Citigroup boosted their price target on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.09.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Level Four Advisory Services LLC increased its position in shares of Edwards Lifesciences by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC boosted its position in Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after acquiring an additional 120 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares during the period. Prosperity Consulting Group LLC raised its position in shares of Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares in the last quarter. Finally, Howard Capital Management Inc. raised its position in shares of Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after acquiring an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.